Smoking cessation and reduction in people with chronic mental illness

BMJ (Online)

Volumn 351, Issue , 2015, Pages

  Tidey, Jennifer W ^a   E Miller, Mollie ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NICOTINE GUM; NICOTINE LOZENGE; NICOTINE PATCH; PLACEBO; VARENICLINE; NICOTINIC AGENT;

ANXIETY DISORDER; BIPOLAR DEPRESSION; CHRONIC DISEASE; COGNITIVE THERAPY; COMORBIDITY; ELECTRONIC CIGARETTE; HUMAN; MAJOR DEPRESSION; MENTAL DISEASE; MOTIVATIONAL INTERVIEWING; NICOTINE REPLACEMENT THERAPY; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOEDUCATION; RECURRENCE RISK; REINFORCEMENT; REVIEW; SCHIZOPHRENIA; SMOKING CESSATION; TOBACCO DEPENDENCE; BIPOLAR DISORDER; EPIDEMIOLOGY; MENTAL PATIENT; PREVALENCE; PROCEDURES; PSYCHOLOGY; SMOKING; UNITED KINGDOM; UNITED STATES; UTILIZATION;

ANXIETY DISORDERS; BIPOLAR DISORDER; BUPROPION; ELECTRONIC CIGARETTES; GREAT BRITAIN; HUMANS; MENTAL DISORDERS; MENTALLY ILL PERSONS; NICOTINIC AGONISTS; PREVALENCE; REINFORCEMENT (PSYCHOLOGY); SCHIZOPHRENIA; SMOKING; SMOKING CESSATION; STRESS DISORDERS, POST-TRAUMATIC; TOBACCO USE CESSATION PRODUCTS; UNITED STATES; VARENICLINE;

EID: 84947460936     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h4065     Document Type: Review

References (155)

1. Lasser K, Boyd JW, Woolhandler S, et al. Smoking and mental illness: a population-based prevalence study. JAMA 2000;284:2606-10
2. Lawrence D, Mitrou F, Zubrick SR. Smoking and mental illness: results from population surveys in Australia and the United States. BMC Public Health 2009;9:285
3. Hartz SM, Pato CN, Medeiros H, et al. Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry 2014;71:248-54
4. Smith PH, Mazure CM, McKee SA. Smoking and mental illness in the US population. Tob Control 2014;23:e147-53
5. Weinberger AH, Pilver CE, Desai RA, et al. The relationship of major depressive disorder and gender to changes in smoking for current and former smokers: longitudinal evaluation in the US population. Addiction 2012;107:1847-56
6. Cook BL, Wayne GF, Kafali EN, et al. Trends in smoking among adults with mental illness and association between mental health treatment and smoking cessation. JAMA 2014;311:172-82
7. Callaghan RC, Veldhuizen S, Jeysingh T, et al. Patterns of tobacco-related mortality among individuals diagnosed with schizophrenia, bipolar disorder, or depression. J Psychiatr Res 2014;48:102-10
8. Kelly DL, McMahon RP, Wehring HJ, et al. Cigarette smoking and mortality risk in people with schizophrenia. Schizophr Bull 2011;37:832-8
9. Hughes JR, Hatsukami DK, Mitchell JE, et al. Prevalence of smoking among psychiatric patients. Am J Psychiatry 1986;143:993-7
10. Olincy A, Young DA, Freedman R. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol Psychiatry 1997;42:1-5
11. Ziedonis DM, George TP. Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull 1997;23:247-54
12. Addington J, el-Guebaly N, Campbell W, et al. Smoking cessation treatment for patients with schizophrenia. Am J Psychiatry 1998;155:974-6
13. George TP, Ziedonis DM, Feingold A, , et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 2000;157:1835-42
14. Chou K-R, Chen R, Lee J-F, et al. The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia. Int J Nurs Stud 2004;41:321-30
15. Baker A, Richmond R, Haile M, et al. A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. Am J Psychiatry 2006;163:1934-42
16. Baker A, Richmond R, Lewin TJ, et al. Cigarette smoking and psychosis: naturalistic follow up 4 years after an intervention trial. Aust N Z J Psychiatry 2010;44:342-50
17. Horst WD, Klein MW, Williams D, et al. Extended use of nicotine replacement therapy to maintain smoking cessation in persons with schizophrenia. Neuropsychiatr Dis Treat 2005;1:349-55
18. Carroll FI, Blough BE, Mascarella SW, et al. Bupropion and bupropion analogs as treatments for CNS disorders. Adv Pharmacol 2014;69:177-216
19. Weiner E, Ball MP, Summerfelt A, et al. Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia. Am J Psychiatry 2001;158:635-7
20. Evins AE, Mays VK, Rigotti NA, et al. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res 2001;3:397-403
21. Evins AE, Cather C, Rigotti NA, et al. Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction. J Clin Psychiatry 2004;65:307-11
22. George TP, Vessicchio JC, Termine A, et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry 2002;52:53-61
23. Evins AE, Cather C, Deckersbach T, et al. A double-blind placebocontrolled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol 2005;25:218-25
24. Evins AE, Cather C, Culhane MA, et al. A 12-week double-blind, placebo-controlled study of bupropion SR added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol 2007;27:380-6
25. George TP, Vessicchio JC, Sacco KA, et al. A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol Psychiatry 2008;63:1092-6
26. Weiner E, Ball MP, Buchholz AS, et al. Bupropion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta-Analysis. J Clin Psychiatry 2012;73:95-102
27. Cather C, Dyer MA, Burrell HA, et al. An open trial of relapse prevention therapy for smokers with schizophrenia. J Dual Diagn 2013;9:87-93
28. Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol 2006;70:801-5
29. Cahill K, Stevens S, Lancaster T. Pharmacological treatments for smoking cessation. JAMA 2014;311:193-4
30. Weiner E, Buchholz A, Coffay A, et al. Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study. Schizophr Res 2011;129:94-5
31. Williams JM, Anthenelli RM, Morris CD, et al. A randomized, doubleblind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2012;73:654-60
32. Evins AE, Cather C, Pratt SA, et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA 2014;311:145-54
33. Williams JM, Steinberg ML, Zimmermann MH, et al. Comparison of two intensities of tobacco dependence counseling in schizophrenia and schizoaffective disorder. J Subst Abuse Treat 2010;38:384-93
34. Steinberg ML, Ziedonis DM, Krejci JA, et al. Motivational interviewing with personalized feedback: a brief intervention for motivating smokers with schizophrenia to seek treatment for tobacco dependence. J Consult Clin Psychol 2004;72:723-8
35. Roll JM, Higgins ST, Steingard S, et al. Use of monetary reinforcement to reduce the cigarette smoking of persons with schizophrenia: a feasibility study. Exp Clin Psychopharmacol 1998;6:157-61
36. Tidey JW, O'Neill SC, Higgins ST. Contingent monetary reinforcement of smoking reductions, with and without transdermal nicotine, in outpatients with schizophrenia. Exp Clin Psychopharmacol 2002;10:241-7
37. Gallagher SM, Penn PE, Schindler E, et al. A comparison of smoking cessation treatments for persons with schizophrenia and other serious mental illnesses. J Psychoactive Drugs 2007;39:487-97
38. Tidey JW, Rohsenow DJ, Kaplan GB, et al. Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia. Psychopharmacology (Berl) 2011;217:279-87
39. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev 2013;2:CD007253
40. Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update. Am J Prev Med 2008;35:158-76
41. McChargue DE, Gulliver SB, Hitsman B. Would smokers with schizophrenia benefit from a more flexible approach to smoking treatment? Addiction 2002;97:785-93
42. Hughes JR, Carpenter MJ. Does smoking reduction increase future cessation and decrease disease risk? A qualitative review. Nicotine Tob Res 2006;8:739-49
43. Asfar T, Ebbert JO, Klesges RC, et al. Do smoking reduction interventions promote cessation in smokers not ready to quit? Addict Behav 2011;36:764-8
44. Ziedonis D, Hitsman B, Beckham JC, et al. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine Tob Res 2008;10:1691-715
45. Tidey JW, Rohsenow DJ, Kaplan GB, et al. Cigarette smoking topography in smokers with schizophrenia and matched non-psychiatric controls. Drug Alcohol Depend 2005;80:259-65
46. Williams JM, Gandhi KK, Lu SE, et al. Shorter interpuff interval is associated with higher nicotine intake in smokers with schizophrenia. Drug Alcohol Depend 2011;118:313-9
47. Dalack GW, Healey DJ, Meador-Woodruff JH. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry 1998;155:1490-501
48. Kumari V, Postma P. Nicotine use in schizophrenia: the self-medication hypothesis. Neurosci Biobehav Rev 2005;29:1021-34
49. Adler LE, Hoffer LD, Wiser A, et al. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 1993;150:1856-61
50. Martin LF, Freedman R. Schizophrenia and the a7 nicotinic acetylcholine receptor. Int Rev Neurobiol 2007;78:225-46
51. Esterlis I, Ranganathan M, Bois F, et al. In vivo evidence for B2 nicotinic acetylcholine receptor subunit upregulation in smokers as compared with nonsmokers with schizophrenia. Biol Psychiatry 2013;76:495-502
52. D'Souza DC, Esterlis I, Carbuto M, et al. Lower B2-nicotinic acetylcholine receptor availability in smokers with schizophrenia. Am J Psychiatry 2012;169:326-34
53. Wing VC, Wass CE, Soh DW, et al. A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia. Ann N Y Acad Sci 2012;1248:89-106
54. George TP, Vessicchio JC, Termine A, et al. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology 2002;26:75-85
55. Barr RS, Culhane MA, Jubelt LE, et al. The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology 2008;33:480-90
56. Hahn B, Harvey AN, Concheiro-Guisan M, et al. A test of the cognitive self-medication hypothesis of tobacco smoking in schizophrenia. Biol Psychiatry 2013;74:436-43
57. Beratis S, Katrivanou A, Gourzis P. Factors affecting smoking in schizophrenia. Compr Psychiatry 2001;42:393-402
58. Riala K, Hakko H, Isohanni M, et al. Is initiation of smoking associated with the prodromal phase of schizophrenia? J Psychiatry Neurosci 2005;30:26-32
59. Chambers RA, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry 2001;50:71-83
60. Brunzell DH, McIntosh JM. Alpha7 nicotinic acetylcholine receptors modulate motivation to self-Administer nicotine: implications for smoking and schizophrenia. Neuropsychopharmacology 2012;37:1134-43
61. Spring B, Pingitore R, McChargue DE. Reward value of cigarette smoking for comparably heavy smoking schizophrenic, depressed, and nonpatient smokers. Am J Psychiatry 2003;160:316-22
62. Thornton LK, Baker AL, Lewin TJ, et al. Reasons for substance use among people with mental disorders. Addict Behav 2012;37:427-34
63. Tidey JW, Colby SM, Xavier EM. Effects of smoking abstinence on cigarette craving, nicotine withdrawal, and nicotine reinforcement in smokers with and without schizophrenia. Nicotine Tob Res 2014;16:326-34
64. Dalack GW, Becks L, Hill E, et al. Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia. Neuropsychopharmacology 1999;21:195-202
65. Moss TG, Sacco KA, Allen TM, et al. Prefrontal cognitive dysfunction is associated with tobacco dependence treatment failure in smokers with schizophrenia. Drug Alcohol Depend 2009;104:94-9
66. Steinberg ML, Williams JM, Gandhi KK, et al. Task persistence predicts smoking cessation in smokers with and without schizophrenia. Psychol Addict Behav 2012;26:850-8
67. Hitsman B, Papandonatos GD, McChargue DE, et al. Past major depression and smoking cessation outcome: a systematic review and meta-Analysis update. Addiction 2013;108:294-306
68. Strong DR, Cameron A, Feuer S, et al. Single versus recurrent depression history: differentiating risk factors among current US smokers. Drug Alc Depend 2010;109:90-5
69. Leventhal AM, Zvolensky MJ. Anxiety, depression, and cigarette smoking: a transdiagnostic vulnerability framework to understanding emotion-smoking comorbidity. Psychol Bull 2014;141:176-212
70. Weinberger AH, Mazure CM, Morlett A, et al. Two decades of smoking cessation treatment research on smokers with depression: 1990-2010. Nicotine Tob Res 2013;15:1014-31
71. Gierisch JM, Bastian LA, Calhoun PS, et al. Smoking cessation interventions for patients with depression: a systematic review and meta-Analysis. J Gen Intern Med 2011;27:351-60
72. Brown RA, Niaura R, Lloyd-Richardson EE, et al. Bupropion and cognitive-behavioral treatment for depression in smoking cessation. Nicotine Tob Res 2007;9:721-30
73. Hall SM, Reus VI, Munoz RF, et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 1998;55:683-90
74. Cox LS, Patten CA, Niaura RS, et al. Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression. J Gen Intern Med 2004;19:828-34
75. Anthenelli RM, Morris C, Ramey TS, et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. Ann Intern Med 2013;159:390-400
76. US Food and Drug Administration. Drug safety newsletter. www.fda.gov/downloads/Drugs/DrugSafety/DrugSafetyNewsletter/ucm107318.pdf.
77. Frye MA, Ebbert JO, Prince CA, et al. A feasibility study of varenicline for smoking cessation in bipolar patients with subsyndromal depression. J Clin Psychopharmacol 2013;33:821-3
78. Weinberger AH, Vessicchio JC, Sacco KA, et al. A preliminary study of sustained-release bupropion for smoking cessation in bipolar disorder. J Clin Psychopharmacol 2008;28:584-7
79. Wu BS, Weinberger AH, Mancuso E, et al. A preliminary feasibility study of varenicline for smoking cessation in bipolar disorder. J Dual Diagn 2012;8:131-2
80. Chengappa KN, Perkins KA, Brar JS, et al. Varenicline for smoking cessation in bipolar disorder: a randomized, double-blind, placebocontrolled study. J Clin Psychiatry 2014;75:765-72
81. Kendler KS, Neale MC, MacLean CJ, et al. Smoking and major depression. A causal analysis. Arch Gen Psychiatry 1993;50:36-43
82. Brown RA, Lewinsohn PM, Seeley JR, et al. Cigarette smoking, major depression, and other psychiatric disorders among adolescents. J Am Acad Child Adolesc Psychiatry 1996;35:1602-10
83. Breslau N, Peterson EL, Schultz LR, et al. Major depression and stages of smoking. A longitudinal investigation. Arch Gen Psychiatry 1998;55:161-6
84. Martinez-Ortega JM, Goldstein BI, Gutierrez-Rojas L, et al. Temporal sequencing of nicotine dependence and bipolar disorder in the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). J Psychiatr Res 2013;47:858-64
85. Hartz SM, Lin P, Edenberg HJ, et al. Genetic association of bipolar disorder with the b(3) nicotinic receptor subunit gene. Psychiatr Genet 2011;21:77-84
86. Weinberger AH, George TP, McKee SA. Differences in smoking expectancies in smokers with and without a history of major depression. Addict Behav 2011;36:434-7
87. Siru R, Hulse GK, Tait RJ. Assessing motivation to quit smoking in people with mental illness: a review. Addiction 2009;104:719-33
88. Breslau N, Kilbey MM, Andreski P. Nicotine withdrawal symptoms and psychiatric disorders: findings from an epidemiologic study of young adults. Am J Psychiatry 1992;149:464-9
89. Weinberger AH, Maciejewski PK, McKee SA, et al. Gender differences in associations between lifetime alcohol, depression, panic disorder, and posttraumatic stress disorder and tobacco withdrawal. Am J Addict 2009;18:140-7
90. Weinberger AH, Desai RA, McKee SA. Nicotine withdrawal in US smokers with current mood, anxiety, alcohol use, and substance use disorders. Drug Alcohol Depend 2010;108:7-12
91. Philip NS, Carpenter LL, Tyrka AR, et al. Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature. Psychopharmacology (Berl) 2010;212:1-12
92. Mineur YS, Picciotto MR. Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. Trends Pharmacol Sci 2010;31:580-6
93. Bacher I, Houle S, Xu X, et al. Monoamine oxidase A binding in the prefrontal and anterior cingulate cortices during acute withdrawal from heavy cigarette smoking. Arch Gen Psychiatry 2011;68:817-26
94. Burgess ES, Brown RA, Kahler CW, et al. Patterns of change in depressive symptoms during smoking cessation: who's at risk for relapse? J Consult Clin Psychol 2002;70:356-61
95. Cavazos-Rehg PA, Breslau N, Hatsukami D, et al. Smoking cessation is associated with lower rates of mood/anxiety and alcohol use disorders. Psychol Med 2014;44:2523-35
96. Taylor G, McNeill A, Girling A, et al. Change in mental health after smoking cessation: systematic review and meta-Analysis. BMJ 2014;348:g1151
97. Perkins KA, Karelitz JL, Giedgowd GE, et al. Differences in negative mood-induced smoking reinforcement due to distress tolerance, anxiety sensitivity, and depression history. Psychopharmacology 2010;210:25-34
98. Malpass D, Higgs S. Acute psychomotor, subjective and physiological responses to smoking in depressed outpatient smokers and matched controls. Psychopharmacology (Berl) 2007;190:363-72
99. D'haenen HA, Bossuyt A. Dopamine D2 receptors in depression measured with single photon emission computed tomography. Biol Psychiatry 1994;35:128-32
100. Shah PJ, Ogilvie AD, Goodwin GM, et al. Clinical and psychometric correlates of dopamine D2 binding in depression. Psychol Med 1997;27:1247-56
101. Brody AL, Olmstead RE, Abrams AL, et al. Effect of a history of major depressive disorder on smoking-induced dopamine release. Biol Psychiatry 2009;66:898-901
102. Cook JW, Spring B, McChargue D. Influence of nicotine on positive affect in anhedonic smokers. Psychopharmacology (Berl) 2007;192:87-95
103. Cook J, Spring B, McChargue D, et al. Effects of anhedonia on days to relapse among smokers with a history of depression: a brief report. Nicotine Tob Res 2010;12:978-82
104. Leventhal AM, Waters AJ, Kahler CW, et al. Relations between anhedonia and smoking motivation. Nicotine Tob Res 2009;11:1047-54
105. Goelz PM, Audrain-McGovern JE, Hitsman B, et al. The association between changes in alternative reinforcers and short-term smoking cessation. Drug Alcohol Depend 2014;138:67-74
106. Berk M, Ng F, Wang WV, et al.. Going up in smoke: tobacco smoking is associated with worse treatment outcomes in mania. J Affect Disord 2008;110:126-34
107. Goldstein BI, Birmaher B, Axelson DA, et al. Significance of cigarette smoking among youths with bipolar disorder. Am J Addict 2008;17:364-71
108. Heffner JL, DelBello MP, Fleck DE, et al. Cigarette smoking in the early course of bipolar disorder: association with ages-At-onset of alcohol and marijuana use. Bipolar Disord 2008;10:838-45
109. Heffner JL, Anthenelli RM, Adler CM, et al. Prevalence and correlates of heavy smoking and nicotine dependence in adolescents with bipolar and cannabis use disorders. Psychiatry Res 2013;210:857-62
110. Ostacher MJ, Nierenberg AA, Perlis RH, et al. The relationship between smoking and suicidal behavior, comorbidity, and course of illness in bipolar disorder. J Clin Psychiatry 2006;67:1907-11
111. Waxmonsky JA, Thomas MR, Miklowitz DJ, et al. Prevalence and correlates of tobacco use in bipolar disorder: data from the first 2000 participants in the Systematic Treatment Enhancement Program. Gen Hosp Psychiatry 2005;27:321-8
112. Prochaska JJ, Reyes RS, Schroeder SA, et al. An online survey of tobacco use, intentions to quit, and cessation strategies among people living with bipolar disorder. Bipolar Disord 2011;13:466-73
113. Morisano D, Wing VC, Sacco KA, et al. Effects of tobacco smoking on neuropsychological function in schizophrenia in comparison to other psychiatric disorders and non-psychiatric controls. Am J Addict 2013;22:46-53
114. Goodwin RD, Wall MM, Choo T, et al. Changes in the prevalence of mood and anxiety disorders among male and female current smokers in the United States: 1990-2001. Ann Epidemiol 2014;24:493-7
115. Piper ME, Smith SS, Schlam TR, et al. Psychiatric disorders in smokers seeking treatment for tobacco dependence: relations with tobacco dependence and cessation. J Consult Clin Psychol 2010;78:13-23
116. Piper ME, Cook JW, Schlam TR, et al. Anxiety diagnoses in smokers seeking cessation treatment: relations with tobacco dependence, withdrawal, outcome and response to treatment. Addiction 2011;106:418-27
117. Evins AE, Culhane MA, Alpert JE, et al. A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders. J Clin Psychopharmacol 2008;28:660-6
118. Jiang F, Li S, Pan L, et al. Association of anxiety disorders with the risk of smoking behaviors: a meta-Analysis of prospective observational studies. Drug Alcohol Depend 2014;145:69-76
119. Moylan S, Jacka FN, Pasco JA, et al. Cigarette smoking, nicotine dependence and anxiety disorders: a systematic review of populationbased, epidemiological studies. BMC Med 2012;10:123
120. Moylan S, Jacka FN, Pasco JA, et al. How cigarette smoking may increase the risk of anxiety symptoms and anxiety disorders: a critical review of biological pathways. Brain Behav 2013;3:302-26
121. Buckner JD, Zvolensky MJ, Jeffries ER, et al. Robust impact of social anxiety in relation to coping motives and expectancies, barriers to quitting, and cessation-related problems. Exp Clin Psychopharmacol 2014;22:341-7
122. Marshall EC, Zvolensky MJ, Vujanovic AA, et al. Evaluation of smoking characteristics among community-recruited daily smokers with and without posttraumatic stress disorder and panic psychopathology. J Anxiety Disord 2008;22:1214-26
123. Watson NL, VanderVeen JW, Cohen LM, et al. Examining the interrelationships between social anxiety, smoking to cope, and cigarette craving. Addict Behav 2012;37:986-9
124. Zvolensky MJ, Schmidt NB, Antony MM, et al. Evaluating the role of panic disorder in emotional sensitivity processes involved with smoking. J Anxiety Disord 2005;19:673-86
125. Zehe JM, Colder CR, Read JP, et al. Social and generalized anxiety symptoms and alcohol and cigarette use in early adolescence: the moderating role of perceived peer norms. Addict Behav 2013;38:1931-9
126. Marshall EC, Johnson K, Bergman J, et al. Anxiety sensitivity and panic reactivity to bodily sensations: relation to quit-day (acute) nicotine withdrawal symptom severity among daily smokers making a self-guided quit attempt. Exp Clin Psychopharmacol 2009;17:356-64
127. Smith PH, Homish GG, Giovino GA, et al. Cigarette smoking and mental illness: a study of nicotine withdrawal. Am J Public Health 2014;104:e127-33
128. Kimbrel NA, Morissette SB, Gulliver SB, et al. The effect of social anxiety on urge and craving among smokers with and without anxiety disorders. Drug Alcohol Depend 2014;135:59-64
129. Zvolensky MJ, Baker KM, Leen-Feldner E, et al. Anxiety sensitivity: association with intensity of retrospectively-rated smoking-related withdrawal symptoms and motivation to quit. Cogn Behav Ther 2004;33:114-25
130. Zvolensky MJ, Vujanovic AA, Miller MO, et al. Incremental validity of anxiety sensitivity in terms of motivation to quit, reasons for quitting, and barriers to quitting among community-recruited daily smokers. Nicotine Tob Res 2007;9:965-75
131. McFall M, Saxon AJ, Thompson CE, et al. Improving the rates of quitting smoking for veterans with posttraumatic stress disorder. Am J Psychiatry 2005;162:1311-9
132. McFall M, Saxon AJ, Malte CA, et al. Integrating tobacco cessation into mental health care for posttraumatic stress disorder: a randomized controlled trial. JAMA 2010;304:2485-93
133. Hertzberg MA, Moore SD, Feldman ME, et al. A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder. J Clin Psychopharmacol 2001;21:94-8
134. Hertzberg JS, Carpenter VL, Kirby AC, et al. Mobile contingency management as an adjunctive smoking cessation treatment for smokers with posttraumatic stress disorder. Nicotine Tob Res 2013;15:1934-8
135. Beckham JC, Roodman AA, Shipley RH, et al. Smoking in Vietnam combat veterans with post-traumatic stress disorder. J Trauma Stress 1995;8:461-72
136. Calhoun PS, Levin HF, Dedert EA, et al. The relationship between posttraumatic stress disorder and smoking outcome expectancies among US military veterans who served since September 11, 2001. J Trauma Stress 2011;24:303-8
137. Beckham JC, Kirby AC, Feldman ME, et al. Prevalence and correlates of heavy smoking in Vietnam veterans with chronic posttraumatic stress disorder. Addict Behav 1997;22:637-47
138. Feldner MT, Babson KA, Zvolensky MJ, et al. Posttraumatic stress symptoms and smoking to reduce negative affect: an investigation of trauma-exposed daily smokers. Addict Behav 2007;32:214-27
139. Carmody TP, McFall M, Saxon AJ, et al. Smoking outcome expectancies in military veteran smokers with posttraumatic stress disorder. Nicotine Tob Res 2012;14:919-26
140. Beckham JC, Calhoun PS, Dennis MF, et al. Predictors of lapse in first week of smoking abstinence in PTSD and non-PTSD smokers. Nicotine Tob Res 2013;15:1122-9
141. Dedert EA, Dennis PA, Swinkels CM, et al. Ecological momentary assessment of posttraumatic stress disorder symptoms during a smoking quit attempt. Nicotine Tob Res 2014;16:430-6
142. Shucard JL, McCabe DC, Szymanski H. An event-related potential study of attention deficits in posttraumatic stress disorder during auditory and visual Go/NoGo continuous performance tasks. Biol Psychol 2008;79:223-33
143. Vasterling JJ, Brailey K, Constans JI, et al. Attention and memory dysfunction in posttraumatic stress disorder. Neuropsychology 1998;12:125-33
144. Ashare RL, Falcone M, Lerman C. Cognitive function during nicotine withdrawal: Implications for nicotine dependence treatment. Neuropharmacology 2014;76:581-91
145. Vrana SR, Calhoun PS, McClernon FJ, et al. Effects of smoking on the acoustic startle response and prepulse inhibition in smokers with and without posttraumatic stress disorder. Psychopharmacology (Berl) 2013;230:477-85
146. Dedert EA, Calhoun PS, Harper LA, et al. Smoking withdrawal in smokers with and without posttraumatic stress disorder. Nicotine Tob Res 2012;14:372-6
147. Farsalinos KE, Polosa R. Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review. Ther Adv Drug Saf 2014;5:67-86
148. McRobbie H, Bullen C, Hartmann-Boyce J, et al. Electronic cigarettes for smoking cessation and reduction. Cochrane Database Syst Rev 2014;12:CD010216
149. Caponnetto P, Auditore R, Russo C, et al. Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study. Int J Environ Res Public Health 2013;10:446-61
150. Benowitz NL, Henningfield JE. Reducing the nicotine content to make cigarettes less addictive. Tob Control 2013;22(suppl 1):i14-7
151. WHO. WHO framework convention on tobacco control. 2003. www.who. int/fctc/text-download/en.
152. Donny EC, Hatsukami DK, Benowitz NL, et al. Reduced nicotine product standards for combustible tobacco: building an empirical basis for effective regulation. Prev Med 2014;68C:17-22
153. Hatsukami DK, Kotlyar M, Hertsgaard LA, et al. Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessation. Addiction 2010;105:343-55
154. Tidey JW, Rohsenow DJ, Kaplan GB, et al. Separate and combined effects of very low nicotine cigarettes and nicotine replacement in smokers with schizophrenia and controls. Nicotine Tob Res 2013;15:121-9
155. Royal Australian College of General Practitioners. Supporting smoking cessation: a guide for health professionals. 2011; updated 2014. www. racgp.org.au/your-practice/guidelines/smoking-cessation.